Nanobac Pharmaceuticals, Incorporated (NNBP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2007 | 4.91 Million USD | 2.08% |
| 2006 | 4.81 Million USD | 69.66% |
| 2005 | 2.83 Million USD | -62.66% |
| 2004 | 7.6 Million USD | 181.47% |
| 2003 | 2.7 Million USD | 83.03% |
| 2002 | 1.47 Million USD | 0.0% |
| 1999 | 2.36 Million USD | 15.51% |
| 1998 | 2.05 Million USD | 65.23% |
| 1997 | 1.24 Million USD | 63.31% |
| 1996 | 759.76 Thousand USD | 169.07% |
| 1995 | -1.1 Million USD | -320.0% |
| 1994 | 500 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2007 Q1 | 2.55 Million USD | 39.63% |
| 2007 FY | 4.91 Million USD | 2.08% |
| 2007 Q4 | 1.14 Million USD | 113.34% |
| 2007 Q3 | 535.48 Thousand USD | -21.24% |
| 2007 Q2 | 679.91 Thousand USD | -73.42% |
| 2006 FY | 4.81 Million USD | 69.66% |
| 2006 Q1 | 1.43 Million USD | 74.46% |
| 2006 Q3 | 736.36 Thousand USD | -9.0% |
| 2006 Q4 | 1.83 Million USD | 148.75% |
| 2006 Q2 | 809.17 Thousand USD | -43.7% |
| 2005 Q4 | 823.88 Thousand USD | 26.98% |
| 2005 Q3 | 648.85 Thousand USD | 8.57% |
| 2005 Q2 | 597.64 Thousand USD | -22.11% |
| 2005 FY | 2.83 Million USD | -62.66% |
| 2005 Q1 | 767.3 Thousand USD | -37.67% |
| 2004 Q1 | 4.14 Million USD | 2415.45% |
| 2004 FY | 7.6 Million USD | 181.47% |
| 2004 Q4 | 1.23 Million USD | 32.87% |
| 2004 Q3 | 926.5 Thousand USD | -28.57% |
| 2004 Q2 | 1.29 Million USD | -68.71% |
| 2003 Q4 | 164.8 Thousand USD | -82.63% |
| 2003 FY | 2.7 Million USD | 83.03% |
| 2003 Q3 | 948.76 Thousand USD | 93.01% |
| 2003 Q1 | 579.69 Thousand USD | 0.0% |
| 2003 Q2 | 491.55 Thousand USD | -15.2% |
| 2002 FY | 1.47 Million USD | 0.0% |
| 2000 Q2 | 755.53 Thousand USD | -12.23% |
| 2000 Q1 | 860.83 Thousand USD | -24.54% |
| 1999 FY | 2.36 Million USD | 15.51% |
| 1999 Q4 | 1.14 Million USD | 223.73% |
| 1999 Q3 | 352.37 Thousand USD | 0.0% |
| 1998 FY | 2.05 Million USD | 65.23% |
| 1997 Q1 | -200 Thousand USD | 64.27% |
| 1997 FY | 1.24 Million USD | 63.31% |
| 1996 Q1 | 200 Thousand USD | 300.0% |
| 1996 Q2 | 100 Thousand USD | -50.0% |
| 1996 FY | 759.76 Thousand USD | 169.07% |
| 1996 Q3 | -500 Thousand USD | -600.0% |
| 1996 Q4 | -559.76 Thousand USD | -11.95% |
| 1995 Q2 | -300 Thousand USD | -200.0% |
| 1995 Q4 | -100 Thousand USD | 66.67% |
| 1995 Q3 | -300 Thousand USD | 0.0% |
| 1995 Q1 | -100 Thousand USD | -200.0% |
| 1995 FY | -1.1 Million USD | -320.0% |
| 1994 Q2 | 900 Thousand USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | -88.89% |
| 1994 Q4 | 100 Thousand USD | 0.0% |
| 1994 FY | 500 Thousand USD | 0.0% |
| 1994 Q1 | 900 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 468.032% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 197.429% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 127.539% |
| Nascent Biotech, Inc. | -2.22 Million USD | 320.407% |
| Rebus Holdings, Inc. | -664 Thousand USD | 840.182% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 93.995% |
| Qrons Inc. | -643.67 Thousand USD | 863.552% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 1361.599% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 108.854% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 1282.926% |
| Skye Bioscience, Inc. | -13.67 Million USD | 135.949% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 106.846% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 1977.846% |
| SQZ Biotechnologies Company | -75.82 Million USD | 106.482% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 272.419% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 419.964% |
| Mesoblast Limited | -84.14 Million USD | 105.841% |
| Marizyme, Inc. | -34.08 Million USD | 114.419% |
| Genus plc | 6.4 Million USD | 23.206% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 49.553% |
| Pharming Group N.V. | -4.87 Million USD | 200.723% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 347.413% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 627.691% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 158.86% |
| ContraFect Corporation | -56.88 Million USD | 108.639% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 207.906% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 450.559% |
| IMV Inc. | -38.67 Million USD | 112.709% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 278.666% |
| MultiCell Technologies, Inc. | -722.81 USD | 680058.91% |
| ONE Bio Corp. | 13.68 Million USD | 64.077% |
| Accustem Sciences Inc. | -3.74 Million USD | 231.187% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 108.332% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 1117.429% |
| Q BioMed Inc. | -3.44 Million USD | 242.64% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -38.836% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 287.051% |
| Biomind Labs Inc. | -1 Million USD | 586.806% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 108.941% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 269.403% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 173.929% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 363.618% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 16508.958% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 130.97% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 354.31% |
| GB Sciences, Inc. | -1.42 Million USD | 445.989% |
| Alpha Cognition Inc. | -9.7 Million USD | 150.639% |
| HST Global, Inc. | -140.9 Thousand USD | 3587.982% |
| CSL Limited | 3.7 Billion USD | 99.867% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 536.909% |
| Halberd Corporation | -75.05 Thousand USD | 6648.716% |
| Enzolytics Inc. | -2.14 Million USD | 328.724% |
| Agentix Corp. | -1.37 Million USD | 458.286% |
| Resverlogix Corp. | -12.74 Million USD | 138.551% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 255.126% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 101.156% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 570.767% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 268.348% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 411.191% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 244.342% |
| AVAX Technologies, Inc. | 6.69 Million USD | 26.567% |
| Zenith Capital Corp. | -8.94 Million USD | 154.957% |
| Genscript Biotech Corporation | -415.79 Million USD | 101.182% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 28311.991% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 300.17% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 2965.62% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 345.157% |
| Kadimastem Ltd | -3.04 Million USD | 261.658% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 599.446% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 491.307% |
| BioStem Technologies, Inc. | -7.77 Million USD | 163.181% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 2808.109% |
| LadRx Corporation | -3.82 Million USD | 228.538% |
| Cell Source, Inc. | -4.32 Million USD | 213.628% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 815.454% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 815.454% |
| NovAccess Global Inc. | -2.46 Million USD | 299.242% |
| Affymax, Inc. | -15.04 Million USD | 132.665% |
| Itoco Inc. | -919.14 Thousand USD | 634.718% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 215.959% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 539.215% |
| Mobile Lads Corp. | -554.55 Thousand USD | 986.27% |
| CytoDyn Inc. | -18.05 Million USD | 127.217% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 19626.464% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 2333.213% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 970.305% |
| SYBLEU INC | -149.18 Thousand USD | 3394.551% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 370.592% |
| International Stem Cell Corporation | -663 Thousand USD | 841.299% |
| Bioxytran, Inc. | -3.82 Million USD | 228.655% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 9436.647% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 24263.279% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 113.552% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 403.758% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 767.923% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 257.982% |
| Neutra Corp. | -229.48 Thousand USD | 2241.66% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 128.022% |
| PureTech Health plc | -146.19 Million USD | 103.362% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 122.869% |
| IXICO plc | -1.43 Million USD | 442.019% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 151.784% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 104.035% |
| CSL Limited | 3.81 Billion USD | 99.871% |
| Cellectis S.A. | -108.85 Million USD | 104.515% |